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Cardiovascular events are the most frequent cause of death in
patients with chronic renal failure (1–2). Heterotopic calcification
of blood vessel walls occurs frequently with advanced age, ath-
erosclerosis, and diabetes mellitus (3). In chronic renal failure,
autopsy (4–5) and clinical investigations (6) have documented a
higher prevalence of coronary plaques in dialyzed patients com-
pared with the nonuremic population. The risk factors that con-
tribute to the higher prevalence of atherosclerotic lesions in
chronic renal failure include dyslipidemia, hyperhomocysteine-
mia, and hypertension (3). In addition, hyperphosphatemia and
increased calcium-phosphate product are important contributors
to vascular calcifications in patients with uremia (7).
A new, noninvasive imaging technology, electron beam
computed tomography, has demonstrated that both hyperphos-
phatemia and increased calcium-phosphate product cause a
progressive increase in calcium deposition in the coronary
arteries and mitral and aortic valves in patients with advanced
renal failure (8). Hyperphosphatemia associates with ectopic
calcifications, increased risk of calciphylaxis, and calcinosis
(9–10). Figure 1 illustrates direct and indirect mechanisms for
hyperphosphatemia to increase calcium-phosphate product.
High levels of phosphate, due to phosphorus retention, worsen
the secondary hyperparathyroidism commonly present in renal
failure through direct and indirect mechanisms. High phos-
phate enhances parathyroid cell proliferation and parathyroid
hormone (PTH) synthesis and secretion directly and indirectly
through both a reduction in serum calcitriol and ionized cal-
cium levels and a reduction of skeletal resistance to PTH. The
resultant high PTH causes osteitis fibrosa and bone loss and
therefore further increases in calcium-phosphate product (11–
12). In addition to its effects on bone, high PTH, by elevating
cytosolic calcium, could cause microcalcifications, as has been
demonstrated in lung (13) and skin (14). Also, PTH impair-
ment of lipid metabolism and immune cell function (15) could
directly contribute to enhance cardiovascular calcification. The
relative contribution of hyperphosphatemia, high calcium-
phosphate product, and secondary hyperparathyroidism to en-
hance vascular calcification, as well as the mechanisms in-
volved, are incompletely understood.
In recent years, vascular calcification was shown to involve
not a passive deposition of calcium-phosphate crystals on
atherosclerotic vessels but an active process in which vascular
cells elicit osteoblastic functions (16). Furthermore, there is a
paradoxical coincidence of vascular mineralization with bone
loss in human and animal models, which suggests that the same
factors that induce high-turnover bone disease in renal failure
could also mediate vascular calcification. This review presents
the emerging understanding of the mechanisms by which hy-
perphosphatemia and elevated Ca  P product affect vascular
calcification. In addition, we present the biologic interactions
and functional parallels between bone and vascular tissues in
bone-associated proteins and PTH-related peptide (PTH-rP).
Phosphate Regulation of Vascular Calcification
Hyperphosphatemia associates with prosthetic cardiac valve
calcification and osteocalcin deposition in experimental ani-
mals with normal renal function (17). Recent studies have
demonstrated phosphate regulation of vascular calcification
and provided some insights into the mechanisms for phosphate
induction of metastatic calcifications. In vivo studies by Kuro-o
et al. (18), in the KLOTHO-gene mutant mice with a pheno-
type that resembles human aging, demonstrated that, in the
presence of normal serum creatinine, albumin, cholesterol, and
triglyceride levels and with only a mild increase in serum
calcium levels (from 9.5 to 10.6 mg/dl), a two-fold increase in
serum phosphate levels resulted in increased calcium-phos-
phate product as well as the development of vascular calcifi-
cations and osteoporosis that were clearly unrelated to malnu-
trition, abnormal lipid metabolism, or chronic renal failure.
Because hyperphosphatemia was the main determinant of the
increased Ca  P product, Jono et al. (19) assessed the con-
tribution of hyperphosphatemia per se on vascular calcifica-
tion. High phosphorus levels in the incubation media (2
mmol/L P) enhanced calcification in human aortic smooth-
muscle cells. Phosphate-containing mineral deposition, as-
sessed by von Kossa staining and light microscopy, was pre-
dominant in the extracellular regions of the cultures, with the
greatest accumulation at sites of cell multilayering (19). Fur-
thermore, these studies demonstrated that high phosphate di-
rectly increases human aortic smooth-muscle cells calcification
and the expression of the osteoblast-specific genes Osf2/Cbfa-1
and osteocalcin (19) (Figure 2). Both effects of high P are
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mediated by the sodium-phosphate cotransporter Pit-1. Osf2/
Cbfa-1 is the only transcriptional activator of osteoblasts dif-
ferentiation in postnatal life (20). Moreover, Cbfa-1 regulates
the expression of osteocalcin (21), one of the more important
osteoblast-specific genes in vitro and in vivo. These reports
suggest that, in addition to elevating Ca  P product, high P
per se could induce vascular calcification. New studies are
mandatory to address the contribution of increased phosphate
levels in the regulation of Pit-1 function and Osf2/Cbfa-1 and
osteocalcin expression and therefore in bone formation and
arterial calcification in advanced renal failure.
Phosphate Regulation of Vascular Cell
Proliferation
Abnormal proliferation of vascular smooth-muscle cells
(VSMC) is another contributor to the development of atheroscle-
rotic lesions. Cell cycle activity is regulated by proteins of the
growth suppressor family of cyclin-dependent kinase inhibitors,
including p21Cip1/WAF1. p21 has been implicated in arresting
VSMC growth through a thrombospondin-1–associated mecha-
nism (22). Increases in p21 expression limit intimal cell prolifer-
ation in response to arterial injury (23) and correlate with growth
arrest in several other cell types (24). Increases in p21 induce G1
arrest and blocked entry into S phase by the inactivation of
cyclin–cyclin-dependent kinase complexes. Enhanced p21 also
inhibits DNA replication by preventing the formation of a trimer
of proliferating cell nuclear antigen, an essential cofactor for the
activity of DNA polymerase delta.
Interestingly, in uremic rats, whereas phosphate restriction up-
regulates parathyroid p21 expression, thus suppressing uremia-
induced parathyroid growth, high dietary phosphorus prevents the
increase in parathyroid p21 necessary to compensate the mito-
genic stimuli induced by the onset of renal failure (25). A similar
regulation of p21 expression by phosphorus concentrations in
vascular cells could modulate proliferation rates, thus providing
an additional mechanism for phosphorus to contribute to the
cardiovascular pathology of renal failure.
Bone-Associated Proteins in Vascular
Calcification
Numerous studies have supported a new definition of arterial
calcification as an organized process with similarities to bone
formation and a striking association between bone loss and
ectopic calcifications. The current understanding of the asso-
ciation between bone morphogenetic proteins and vascular
calcification in atherosclerotic lesions in humans and animal
models is presented below and summarized in Figure 3. Al-
though increased expression of osteocalcin, osteonectin, bone
morphogenic protein type 2a (BMP-2a) and alkaline phospha-
tase associates with enhanced vascular calcification, higher
content of osteopontin, matrix Gla protein (MGP), and osteo-
protegerin inhibits mineral deposition.
Osteopontin has been associated with both bone mineralization
and ectopic calcification. Two recent studies have investigated the
expression of osteopontin in calcified arteries (26–27). Wada et
al. (28) proposed that osteopontin acts as an inhibitor of calcifi-
cation of VSMC cultures. Jono et al. (29) demonstrated that the
phosphorylation of osteopontin was a required step for inhibition
of vascular cell calcification in VSMC. Thus, osteopontin is not
only a potent bone mineralization regulator but is also an impor-
tant inhibitor of ectopic calcifications.
Gla proteins also participate in the pathophysiology of osteo-
porosis and in the prevention of vascular calcification (30). MGP
is an extracellular matrix protein with high affinity for hydroxy-
apatite. Mice that lack MGP develop arterial calcification as well
as inappropriate bone formation with pathologic fractures during
the first 2 mo of life (31). These findings illustrate that, similar to
osteopontin, MGP is required to promote normal bone formation
and also to inhibit vascular calcification.
Figure 2. Phosphate regulation of vascular smooth muscle-cell calcifica-
tion. In human smooth-muscle cells in culture, high-phosphate medium
(2.0 mmol/L) increases calcification by enhancing intracellular phospho-
rus concentration and inducing osteoblast-specific genes Osf2/Cbfa-1 and
osteocalcin, which directly associate with ectopic calcification. Both
effects are mediated by the sodium-dependent phosphate cotransporter
(NPC) Pit-1 (member of type III family of NPC). Adapted with permis-
sion from Jono et al. (19).
Figure 1. Potential side effects of hyperphosphatemia in renal failure.
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Osteoprotegerin (OPG), a protein that inhibits osteoclasto-
genesis, is an additional player in vascular calcification. In
OPG-deficient mice, Bucay et al. (32) observed a decreased
bone density and increased vascular calcification of the aorta
and renal arteries. Studies by Min et al. (33) indicate that OPG
plays an important role in both pathologic and physiologic
calcification processes. Similar to osteopontin and MGP, OPG
appears to inhibit ectopic calcification.
In contrast to the protective effects of osteopontin, MGP,
and OPG, increases in other bone matrix proteins, osteocalcin,
osteonectin, BMP-2a, and alkaline phosphatase, directly cor-
relate with vascular calcification. Osteocalcin was found in
calcified atherosclerotic plaques and calcified areas within
glutaraldeyde-preserved porcine valves (34). In addition, in-
creased bone formation has been demonstrated in osteocalcin-
deficient mice (35). Studies to clarify the role of osteocalcin in
vascular calcification have demonstrated that high phosphate
increased human aortic smooth-muscle cells calcification by
enhancing osteocalcin and Osf2/Cbfa-1 expression (19). These
findings suggest a direct association between osteocalcin and
ectopic calcifications.
Osteonectin, also known as SPARC or BM40, is a protein
that is localized mainly in mineralized tissues such as bone,
cartilage, and teeth (36). Bini et al. (37) identified osteonec-
tin, osteocalcin, and osteopontin in advanced atherosclerotic
plaques with dystrophic calcification in human thrombotic
carotid arteries. Osteonectin was found in endothelial cells,
VSMC, and macrophages, and its expression associates with
calcium-phosphate deposition (37). Although osteonectin
seems to associate directly with ectopic calcification, the
mechanisms for osteonectin-mediated vascular calcification
remain unclear. Another protein, BMP-2a, which has a
potent osteoblast-differentiating function (38), was found in
human atherosclerotic plaques. A direct association appears
to exist between BMP-2a and vascular calcification (39).
Finally, alkaline phosphatase (ALP) activity may play a role
in calcification of artery cell walls in humans. Shioi et al.
(40) demonstrated that increased levels of ALP accelerate
calcification in bovine vascular smooth-muscle cells. More-
over, levamisole, an ALP inhibitor, blocked bovine vascular
smooth-muscle cell calcification in a dose-dependent man-
ner (40). The presence of ALP in human atherosclerotic
lesions (41) suggests an active role in the promotion of
vascular calcification. More studies are necessary to identify
the precise role of bone-associated proteins in the pathogen-
esis of vascular calcification and the contribution of altered
expression and/or function of these proteins in chronic renal
failure to the higher incidence of vascular calcification in
patients with uremia.
Role of PTH-rP in Vascular Calcification
One more protein appears to play an important role in
modulating calcification of VSMC: the PTH-rP. In an in vitro
calcification model, Jono et al. (42) showed the inhibitory
action of PTH-rP in bovine vascular smooth-muscle cells. In
Figure 3. Vascular calcification and bone-associated proteins. Bone-associated proteins elicit opposing effects on vascular calcification.
Osteocalcin, osteonectin, bone morphogenic protein-2a, and alkaline phosphatase (ALP) are inducers of calcification. In contrast, osteopontin,
matrix Gla protein (MGP), osteoprotegerin, and parathyroid hormone–related peptide (PTHr-peptide) inhibit calcification. In addition to a direct
effect on calcium deposition, high phosphorus could enhance active calcification through induction of Cbfa-1 and osteocalcin expression.
Osteopontin and osteocalcin are the two most critical bone-associated proteins involved in vascular calcification, and their regulation in chronic
renal failure should be further examined. Adapted from Tierney et al. (55).
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addition, the inhibition of calcification by either etidronate or
levamisole involves enhancement of PTH-rP secretion (42).
This in vitro relationship between PTH-rP expression and
vascular calcification has been observed also in an in vivo
model. Nakayama et al. (43) showed that, in coronary athero-
sclerotic smooth-muscle cells, PTH-rP expression correlated
with the severity of atherosclerosis. However, PTH-rP expres-
sion was higher in uncalcified coronary atherosclerotic lesions
than in calcified VSMC (43).
Clearly, these findings showed the in vitro and in vivo associ-
ation between PTH-rP expression and arterial calcification. How-
ever, the mechanisms involved, as well as the regulation of the
expression of PTH-rP and its receptor, the PTH receptor, during
vascular calcification in renal failure, remain to be clarified.
Treatment of Hyperphosphatemia in Renal
Failure
Because vascular calcifications are predictive of higher mor-
bidity and mortality, the control of serum phosphorus and
calcium-phosphate product is important in the prevention of
arterial calcifications in chronic renal failure (7). The current
treatment for the hyperphosphatemia of chronic renal failure
consists of dietary phosphate restriction, dialysis treatment, and
administration of phosphate binders (aluminum salts, calcium
carbonate, or acetate).
The main limitation for effective phosphate restriction in
patients undergoing dialysis is that it requires dietary protein
restriction. Basically, the achievement of a hypophosphoric
diet is against a protein intake of 1.0 to 1.2 g/kg per d, which
is recommended to avoid malnutrition. An average daily and
weekly P balance is depicted in Figure 4. In a patient under-
going dialysis who ingests the adequate amount of protein, the
average daily phosphate intake is 1 to 1.2 g. With an average
60% P absorption, the net balance is 5 g of phosphate per week.
During hemodialysis treatment, phosphate clearance is effi-
cient only during the first 2 h. Serum phosphorus levels do not
change during the second half of dialysis (44). Because hemo-
dialysis removes 900 mg of phosphate three times weekly,
90% of patients with uremia require phosphate binders to
avoid hyperphosphatemia (45). In fact, to achieve a “normal”
phosphorus level that is below 5 mg/dl, 13 to 18 g of calcium
carbonate are required daily (46).
Recent studies have described the limitations of calcium-
based phosphate binders and the calcium overload in patients
with advanced renal failure (8,47). Patients undergoing dialysis
ingest 500 to 800 mg of calcium daily. Additional sources
contribute to the high calcium load: calcium in the dialysate,
calcium supplements, and calcium-based phosphate binders.
Hsu et al. (48) demonstrated that patients undergoing dialysis
are in a positive calcium balance and that the excess calcium is
present in the gastrointestinal tract and soft tissues. In addition,
in patients with uremia, there is an association between ele-
mental calcium intake from calcium-based phosphate binders
and dietary phosphorus as protein (46).
The problem of calcium load in renal failure was empha-
sized 35 yr ago by Clarkson et al. (49). In patients with
advanced renal failure, the ingestion of 20 g of calcium car-
bonate daily for 18 to 30 d caused an important increase in
calcium absorption. Furthermore, increased calcium absorption
was also present in normal controls (49). Clarkson in 1966
concluded: “Unless all of the calcium which is absorbed is laid
in bone the calcium content of the soft tissues may rise and
renal function deterioration increase” (49).
In addition, to control the progression of secondary hyperpara-
thyroidism, oral or intravenous administration of 1,25(OH)2D3 is
commonly used. Because 1,25(OH)2D3 increases intestinal cal-
cium absorption and calcium and phosphate mobilization from
bone, vitamin D therapy further increases the risk of development
of vascular calcification in patients who have an already enhanced
calcium-phosphate product, especially in those who receive cal-
cium salts as phosphate binders.
Despite this modern therapy, more than half of these patients
do not achieve good control of serum phosphorus, calcium-
phosphate product, and PTH levels. New phosphate binders,
poly-allylamine hydrochloride (sevelamer HCl, Renagel; Gen-
zyme, Cambridge, MA) and trivalent iron–containing com-
pounds, have been developed. These compounds do not con-
tain aluminum or calcium and therefore lack the side effects
associated with classical phosphate binders. In the case of
sevelamer HCl, in addition to effectively reducing serum levels
of phosphorus (31%) and PTH (22%) with no hypercalcemia
(Figure 5), it ameliorates lipid abnormalities (50). A reduction
of 30% in low-density lipoprotein cholesterol and an 18%
increase in high-density lipoprotein cholesterol concentration
accompanied sevelamer treatment (50). These findings suggest
the potential of this new phosphate binder to reduce athero-
sclerotic lesions and vascular calcification.
In the case of trivalent iron–containing compounds, in nor-
mal and uremic rats (51), effective inhibition of intestinal
phosphate absorption was demonstrated for both iron(III) ox-
ide-hydroxide dextran (52) and Fe(III) citrate: Fe(III) chloride
(51). Despite no reduction in serum phosphorus, both com-
pounds markedly reduced urinary phosphate excretion. In 13
Figure 4. Phosphate balance in patients undergoing hemodialysis
(HD). From a weekly intake of phosphate of 8.4 grams (1.2 g/d),
60% is absorbed, rendering a net absorption of 5.0 g/wk (0.7 g/d).
Because P removed by standard HD (3 times weekly, 4 h for each
session) is 2.7 g, a positive P balance is 2.3 grams weekly (300
mg/d).
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predialysis patients, with a plasma phosphate level of 2.2 mM,
polynuclear iron hydroxide decreased serum phosphate levels
by 20% in 4 wk with only mild laxative side actions (53).
Studies in 32 patients undergoing dialysis with plasma phos-
phate levels of 2.64 mM showed Fe(III) polymaltose complex
to cause an average 0.38-mM reduction in P by 8 wk, a
decrease such that P did not reach statistical significance and
there was no effect on serum PTH (54). Further information on
the safety of these Fe(III) compounds is mandatory.
In patients with chronic renal failure, increased serum Ca 
P product and hyperphosphatemia are important contributors to
the higher incidence of arterial calcifications and cardiovascu-
lar events. Hyperphosphatemia, by accelerating the progression
of secondary hyperparathyroidism, increases serum PTH and
bone loss. High PTH itself induces increases in intracellular
calcium and abnormal lipid metabolism that promote soft tis-
sue calcifications. Phosphorus-induced and PTH-induced bone
loss elevates Ca  P product and, most likely, the expression
of factors that mediate the strong association between bone loss
and arterial calcification, such as bone-associated proteins.
Direct effects of phosphorus on vascular pathology include the
regulation of vascular cell proliferation as well as the induction
of the expression of the osteoblast-specific bone-forming pro-
teins, Cbfa-1 and osteocalcin. Clearly, the control of serum
phosphorus levels in patients with uremia may reduce vascular
calcification not only by decreasing calcium-phosphate product
but also by reducing serum PTH, thus ameliorating the active
and yet incompletely understood processes common for vas-
cular calcification and bone loss.
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